The present invention relates to arylpiperazines, and to the efficient treatment of an individual afflicted with L-DOPA-induced dyskinesia, which condition typically arises as a consequence of long-term treatment with L-DOPA therapy in Parkinson patients, or with anxiety, the instant treatments comprising administering to the individual an effective amount of an arylpiperazine or a pharmaceutically acceptable salt thereof.